Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097517 | 0.96 | MAPT (0.50) | MAPTHPGDKMT2ATP53KDR | |
| SCHEMBL12108935 | 0.94 | MAPT (0.45) | MAPTHPGDKMT2ATP53KDR | |
| SCHEMBL13152410 | 0.94 | MAPT (0.44) | MAPTHPGDKMT2AKDRNPC1 | |
| SCHEMBL10097682 | 0.93 | MAPT (0.48) | MAPTHPGDKMT2ATP53KDR | |
| SCHEMBL13152308 | 0.92 | HSD17B10 (0.42) | MAPTHPGDTP53KDRNPC1 | |
| SCHEMBL10097427 | 0.91 | KMT2A (0.52) | MAPTKMT2ATP53NPC1 | |
| SCHEMBL10097442 | 0.90 | MAPT (0.47) | MAPTHPGDKMT2ATP53KDR | |
| SCHEMBL13152397 | 0.88 | ALDH1A1 (0.43) | MAPTKMT2ATP53PSEN1PSEN2 | |
| SCHEMBL13152653 | 0.88 | MAPT (0.41) | MAPTHPGDKMT2ATP53KDR | |
| SCHEMBL10251176 | 0.88 | HSD17B10 (0.44) | MAPTTP53KDRLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | MAPT 4477/4885HPGD 3255/4885KMT2A 4464/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | MAPT 4044/4885HPGD 1854/4885KMT2A 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.